Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IVA
IVA logo

IVA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inventiva SA (IVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.720
1 Day change
-6.08%
52 Week Range
7.980
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Inventiva SA (IVA) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. While there are positive analyst ratings and potential upside from upcoming catalysts, the technical indicators are neutral, and there are no significant recent trading signals or news to support immediate action. The lack of financial data and valuation metrics further limits the ability to make a confident buy recommendation.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 50.987, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 5.997, with resistance at 6.246 and support at 5.749.

Positive Catalysts

  • Analyst ratings are highly positive, with price targets ranging from $12 to $18, suggesting significant upside potential. Hedge funds are actively buying, with a 681.82% increase in buying activity over the last quarter. Upcoming Phase 3 data in the second half of the year could act as a major catalyst.

Neutral/Negative Catalysts

  • Technical indicators are neutral to bearish, offering no immediate buy signals. The stock is expected to decline slightly in the next week and month based on candlestick pattern analysis. No recent news or congress trading data is available to support a strong buy case.

Financial Performance

No financial data available for assessment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have initiated or upgraded the stock to Buy or Overweight ratings, with price targets ranging from $12 to $18. They highlight strong fundamentals, upcoming catalysts, and potential upside of up to +100% from current levels.

Wall Street analysts forecast IVA stock price to rise
6 Analyst Rating
Wall Street analysts forecast IVA stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.090
sliders
Low
11
Averages
15.67
High
26
Current: 6.090
sliders
Low
11
Averages
15.67
High
26
Truist
initiated
$13
AI Analysis
2026-03-18
Reason
Truist
Price Target
$13
AI Analysis
2026-03-18
initiated
Reason
Truist initiated coverage of Inventiva with a Buy rating and $13 price target. Lead asset lanifibranor has a unique mechanism and profile among metabolic dysfunction-associated steatohepatitis therapies in development that could make it "an ideal choice" for a niche group of MASH patients with diabetes, the analyst tells investors. Near-term Phase 3 data due in the second half of the year "could result in up to +100% upside from current levels," contends the analyst, who estimates base case third-line use in MASH F2/F3 supports $2.3B worldwide peak adjusted revenue.
Barclays
Overweight
initiated
$18
2026-01-27
Reason
Barclays
Price Target
$18
2026-01-27
initiated
Overweight
Reason
Barclays initiated coverage of Inventiva with an Overweight rating and $18 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IVA
Unlock Now

People Also Watch